Skip to main content
Premium Trial:

Request an Annual Quote

Bionomics Licenses North American, Japanese Market Rights to Gene-Based Epilepsy Test

NEW YORK, Sept. 27 (GenomeWeb News) - Bionomics said yesterday that it has signed a deal giving the North American and Japanese market rights to its gene-based severe myoclonic epilepsy of infancy diagnostic test to Athena Diagnostics.


Under the agreement, Athena will pay Bionomics upfront fees, sales milestones, and royalties. Additional terms were not disclosed.


According to Bionomics, Athena plans to make the product available later this year to the more than 5,000 neurologists for whom it performs diagnostic tests. The company added that it estimates about 240,000 children in the US may be candidates for testing.


The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.